RxDoctor Payments Data

Amanda Ruyle-Ryan

Gerontology · Springfield, ILNPI 1295361533

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,453 of the $3,676 with a category attached, or 66.7%. Medtronic accounts for 73.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $2,031 and has fallen 77.6% since, to $454 in 2024. Among gerontology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,676in general payments, 2019–2025

Across 68 payments — averaging $54.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Sumitomo Pharma America, Inc.$312
  • Astellas Pharma US Inc$157
  • Procept Biorobotics Corporation$152
  • Pfizer$86
  • Merck$52
  • plus $214 from 9 others

What the payments were for

  • Travel & lodging$2,45367%
  • Food & beverage$1,08429%
  • Education$1394%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,676 in reported general payments places this provider in the 90th percentile of 180 gerontology providers in Illinois.

See all gerontology providers in Illinois

Medicare billing

Part B allowed, 2024
$84,906
Medicare patients
669
Services billed
8,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron200$183,137
GemtesaVibegron116$108,254
Mirabegron ErMirabegron65$45,874
Tamsulosin Hcl1,345$20,243
Solifenacin Succinate103$7,064
Finasteride489$5,613
Silodosin44$4,318
Alfuzosin Hcl ErAlfuzosin Hcl170$3,968
Estradiol57$3,933
Oxybutynin Chloride ErOxybutynin Chloride144$3,546
Trospium Chloride64$2,479
Trimethoprim25$2,386
Potassium Citrate ErPotassium Citrate16$1,170
Bethanechol Chloride31$1,120
Desmopressin Acetate20$717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$157$183,137200 claims
Sumitomo Pharma America, Inc.Gemtesa$312$108,254116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 gerontology providers in Illinois.

Other gerontology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →